Teva Pharmaceutical Industries Immediately
- 52-Week Vary
- $11.83
▼
$22.80
- Value Goal
- $22.00
Teva Prescribed drugs Industries Ltd NYSE: TEVA is the world’s largest generic drug maker, with over 500 generic and biosimilar remedies in its broad portfolio. The medical sector large additionally has a line of branded medication driving progress.
Its specialty medicines deal with particular circumstances, together with respiratory illnesses, oncology, and central nervous system (CNS) problems. Its inventory took a 17% tumble within the days following its fourth quarter of 2024 earnings launch. Teva’s cautious full-year 2025 steerage fell wanting consensus analyst estimates. With shares buying and selling at simply 6.8x ahead earnings, worth buyers could view this as a dip shopping for alternative.
The Transformative Yr 2024
Teva Prescribed drugs, like many different giant drug makers and pharmacies like Johnson & Johnson NYSE: JNJ, Allergan plc NYSE: AGN, CVS Well being Co. NYSE: CVS, and Walgreens Boots Alliance Inc. NASDAQ: WBA, had been concerned in settlements for his or her participation within the opioid epidemic. Teva’s black cloud surrounding the opioid settlements dissipated after 2023 when the corporate agreed to make ongoing funds and provide their generic model of Narcan as a part of the settlement. This marks 2024 because the yr of normalization and return to progress.
Teva CEO Richard Francis commented, “2024 marked a transformative yr for Teva, leading to a second consecutive yr of progress, pushed by our generic merchandise and key revolutionary merchandise. Specializing in the rigorous execution of our Pivot to Progress technique all year long, we continued to attain vital milestones in every of its 4 pillars, together with surpassing the outlook for our key revolutionary merchandise, rising our generics enterprise throughout all segments, and accelerating our early-stage revolutionary pipeline, together with the constructive Section 2b outcomes for our duvakitug (anti-Tl1A) asset. These outcomes pave the way in which for pivotal trials in Crohn’s illness and ulcerative colitis, in addition to, probably, different Immunological and fibrotic indications past, in collaboration with our companion, Sanofi.”
Wrapping Up 2024 With a Sturdy End for a Strong Yr
Teva’s This fall 2024 outcomes had been comparatively sturdy. The corporate posted EPS of 71 cents, which met consensus estimates.
Revenues fell 5.1% year-over-year (YoY) to $4.23 billion, beating $4.23 billion consensus estimates.
For the complete yr 2024, revenues rose 6% YoY to $16.5 billion. Its generics enterprise grew 15% in the USA, 6% in Europe, and 15% YoY in worldwide markets. World gross sales of its model medication had been strong.
AUSTEDO exceeded $1.6 billion in revenues, surpassing the corporate’s 2024 outlook.
AJOY revenues rose 17% YoY to $507 million. UZEDY revenues surpassed the $100 million outlook, producing $117 million in 2024.
Steerage Was on the Cautious Aspect
Teva issued its 2025 full-year preliminary steerage for EPS of $2.35 to $2.65 versus $2.78 consensus estimates. Full-year income is predicted to be between $16.8 billion to $17.4 billion versus $17.09 billion consensus estimates. That is what triggered the sell-off in shares.
First-to-Market Generic GLP-1 Remedy in 2025
In January 2025, Teva entered right into a license and provide settlement for a proposed GLP-1 therapy in the USA and Europe. The corporate with be first-to-market with the launch of a generic model of Sandostatin LAR Depot and liraglutide injection 1.8mg. It’s a licensed generic of Victoza.
Liraglutide is a GLP-1 agonist, which is the lively ingredient in Victoza. Victoza is an older GLP-1 drug made by Novo Nordisk A/S NYSE: NVO, maker of semaglutide, the lively ingredient in Ozempic and Wegovy. Victoza was an early GLP-1 used particularly for kind 2 diabetes, with sufferers shedding a median of 6.2 kilos. It paved the way in which for the event of the newer GLP-1 medication Ozempic after which Wegovy for weight reduction.
TEVA Inventory Varieties a Symmetrical Triangle Breakdown
A symmetrical triangle is comprised of a descending (falling) higher trendline resistance converging with an ascending (rising) decrease trendline help on the apex level. A breakout happens when the inventory surges above the higher trendline resistance. A breakdown happens when the inventory collapses beneath the decrease trendline help. A breakout or breakdown turns into eminent because the inventory will get nearer to the apex level because the channel narrows.
TEVA fashioned a symmetrical triangle with the higher descending trendline forming on the $22.80 swing excessive and the ascending decrease trendline help forming on the $19.03 hole fill. TEVA chopped in the direction of the apex level earlier than gapping down on its earnings launch to the $19.75 stage and continuing decrease in the direction of the $17.26 fib. Fibonacci (Fib) pullback help ranges are at $17.26, $16.83, $16.25 and $15.81.
TEVA inventory’s common consensus worth goal is 23.56% greater at $22.00, and its highest analyst worth goal sits at $30.00. It has six analysts’ Purchase scores and a couple of Maintain Rankings. The inventory has a 1.39% quick curiosity.
Bullish buyers can think about using cash-secured places on the Fib pullback help ranges to purchase the dip. If assigned the shares, then writing lined calls at upside Fib ranges executes a wheel technique for revenue.
Earlier than you contemplate Teva Pharmaceutical Industries, you may need to hear this.
MarketBeat retains monitor of Wall Road’s top-rated and finest performing analysis analysts and the shares they suggest to their purchasers each day. MarketBeat has recognized the 5 shares that prime analysts are quietly whispering to their purchasers to purchase now earlier than the broader market catches on… and Teva Pharmaceutical Industries wasn’t on the checklist.
Whereas Teva Pharmaceutical Industries presently has a “Reasonable Purchase” score amongst analysts, top-rated analysts consider these 5 shares are higher buys.
Searching for the subsequent FAANG inventory earlier than everybody has heard about it? Enter your e mail deal with to see which shares MarketBeat analysts assume may turn into the subsequent trillion greenback tech firm.
